Lizneva D. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.

Article  PubMed  Google Scholar 

Norman RJ. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–97.

Article  CAS  PubMed  Google Scholar 

Nandi A. Polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2014;43(1):123–47.

Article  PubMed  Google Scholar 

Rasquin LI, Anastasopoulou C, Mayrin JV. Polycystic ovarian disease. Treasure Island: StatPearls Publishing; 2023.

Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–58.

Article  PubMed  PubMed Central  Google Scholar 

Bagir GS. Body Mass Index below Obesity Threshold Implies Similar Cardiovascular Risk among Various Polycystic Ovary Syndrome Phenotypes. Med Princ Pract. 2016;25(1):61–6.

Article  PubMed  Google Scholar 

Wang FF. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis. Obes Rev. 2018;19(10):1424–45.

Article  PubMed  Google Scholar 

Stepto NK. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28(3):777–84.

Article  CAS  PubMed  Google Scholar 

Mahalingaiah S, Diamanti-Kandarakis E. Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert Opin Ther Targets. 2015;19(11):1561–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubin KH. Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017;102(10):3848–57.

Article  PubMed  Google Scholar 

Li Y. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019;228:167–75.

Article  CAS  PubMed  Google Scholar 

Lashen H. Role of metformin in the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2010;1(3):117–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teede HJ. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–18.

Article  PubMed  PubMed Central  Google Scholar 

Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017;108(3):426–41.

Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome–a reappraisal. Nat Clin Pract Endocrinol Metab. 2008;4(5):272–83.

Article  CAS  PubMed  Google Scholar 

Chen X, He S, Wang D. Effects of metformin on body weight in polycystic ovary syndrome patients: model-based meta-analysis. Expert Rev Clin Pharmacol. 2021;14(1):121–30.

Article  CAS  PubMed  Google Scholar 

Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annu Rev Physiol. 2021;83:503–28.

Article  CAS  PubMed  Google Scholar 

Marinkovic-Radosevic J. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. World J Diabetes. 2021;12(7):932–8.

Article  PubMed  PubMed Central  Google Scholar 

Pruett JE. 2021 Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome. Int J Mol Sci. 2021;22(5):2576.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X. Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species. Int J Mol Sci. 2021;22(11):6044.

Article  CAS  PubMed  PubMed Central  Google Scholar 

DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26.

Article  CAS  PubMed  Google Scholar 

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.

Legro RS. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elkind-Hirsch KE. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021;106(10):3019–33.

Article  PubMed  Google Scholar 

Htike ZZ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–36.

Article  CAS  PubMed  Google Scholar 

Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019;39(2):332–42.

Article  CAS  PubMed  Google Scholar 

Siamashvili M, Davis SN. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2021;14(9):1081–9.

Article  CAS  PubMed  Google Scholar 

Zhang J. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. Front Endocrinol (Lausanne). 2022;13:1003238.

Article  PubMed  Google Scholar 

Cai M. Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial. Diabetes Obes Metab. 2022;24(2):312–20.

Article  CAS  PubMed  Google Scholar 

Javed Z. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clin Endocrinol (Oxf). 2019;90(6):805–13.

Article  CAS  PubMed  Google Scholar 

Zeng Q, Xu X, Xin L. Effect of canagliflozin combined with metformin on endocrine and metabolic levels in overweight and obese women with polycystic ovary syndrome (in Chinese). Maternal & Child Health Care of China. 2022;37(24):4649–52.

CAS  Google Scholar 

McMurray JJV. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995–2008.

Article  CAS  PubMed  Google Scholar 

Zheng RJ. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2022;79(2):e145–52.

Article  CAS  PubMed  Google Scholar 

Perkovic V. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–306.

Article  CAS  PubMed  Google Scholar 

Berni TR, Morgan CL, Rees DA. Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: A population study. J Clin Endocrinol Metab. 2021;106(9):e3369–80.

Wekker V. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(6):942–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Catalano PM. Obesity, insulin resistance, and pregnancy outcome. Reproduction. 2010;140(3):365–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lainez NM, Coss D. obesity, neuroinflammation, and reproductive function. Endocrinology. 2019;160(11):2719–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ormazabal V. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pruett JE. Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition. Biol Sex Differ. 2022;13(1):45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He YL. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obes Metab. 2019;21(6):1311–21.

Article